Solid Biosciences SLDB 深 滬

Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining over 100 points on Wednesday. Shares of Sophia Genetics SA (NASDAQ:SOPH) fell sharply in pre-market trading. Sophia Genetics priced its underwritten public offering of 10.526 million ordinary shares at $4.75 each, ra...

06-17 20:03

美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元

火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>

06-04 11:36

HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25

HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $20 to $25.

06-03 19:58

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Inc. granted 6,580 restricted stock units (RSUs) to a newly hired employee. The RSUs vest in four equal installments annually over four years, contingent on continued employment. The grant was made under the Company’s 2024 Inducement Stock Incentive Plan to induce the employee’s acceptance of employment. Solid Biosciences, a precision genetic medicine company, focuses on developing gene therapy candidates for rare neuromuscular ...

06-01 20:05

美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级

今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元

05-19 10:55

Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price Target

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $16 price target.

05-18 20:34

美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"

今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元

05-14 14:32

Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) Estimate

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.44) by 18.18 percent. This is a 11.86 percent increase over losses of $(0.59) per share

05-13 04:41

Solid Biosciences Doses First Participant In Phase 3 IMPACT DUCHENNE Clinical Trial For SGT-003 In Duchenne Muscular Dystrophy

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory

05-07 20:06

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05-01 20:05